Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 
 
 

PPD reveals COVID-19 assays
September 2020
SHARING OPTIONS:

WILMINGTON, N.C.—PPD Inc. has added five new molecular, serology and functional assays to its laboratory test portfolio, the company announced recently. The assays are designed expressly for COVID-19 vaccine and therapy development programs, and are engineered to run on multiple platforms and be compatible with high-throughput liquid handling to support large numbers of specimens. The assays use reverse transcriptase, polymerase chain reaction (RT-PCR) to detect SARS-CoV-2, and include a qualitative assay targeting spike and nucleocapsid proteins within open read frame 1; a quantitative RT-PCR assay that targets only nucleocapsid proteins; two enzyme-linked immunosorbent assays (ELISA) that detect immunoglobulin G to full-length recombinant protein, one for spike and one for nucleocapsid; and a plate-based functional assay that can detect anti-spike antibodies in human serum capable of preventing infection by blocking ACE2 from binding to the SARS-CoV-2 spike protein.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.